Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
What role might depemokimab play in the stepwise approach to asthma management, especially for patients who have previously failed other biologic therapies?
Do the findings from
PMID 39248309
influence your approach
Related Questions
Do you recommend that your patients with COPD avoid gabapentin or pregabalin entirely, given the increased rate of exacerbations noted in patients on these medications?
What are the potential challenges and benefits of implementing z score thresholds in clinical practice for COPD severity classification, and how might this affect patient outcomes?
How do you choose roflumilast vs ensifentrine in COPD patients with dyspnea despite adequate LABA + LAMA (+ ICS therapy where indicated)?
Should thunderstorm asthma be incorporated into asthma action plans?
Would you treat Scedosporium growth in expectorated sputum in a patient with COPD, pulmonary hypertension, and bronchiectasis, who has chronic dyspnea with exertion, thick sputum production, negative bacterial cultures, and no signs of mold infection on a high resolution CT scan, with no other clinical symptoms of infection?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
How do you choose between dupilumab and mepolizumab for managing COPD in patients with eosinophilia?
How might the introduction of brensocatib as a treatment option impact the use of other anti- inflammatory or antibiotic therapies currently employed in bronchiectasis management?
What is your approach to addressing comorbidities that influence asthma severity?
What is your preferred rescue inhaler for patients with asthma?